<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432872</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT2015002</org_study_id>
    <nct_id>NCT02432872</nct_id>
  </id_info>
  <brief_title>Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years</brief_title>
  <official_title>A Multicenter，Open-label，Radonmized Study on the Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jianxiang Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the escalation dosage of Daunorubicin and
      cytarabine is effective and safety in the treatment of older adult Chinese acute myeloid
      leukemia（AML） patients aged 55 to 65 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the DA 3+7 regimen is the standard therapy in the AML treatment.Escalated dosage of
      daunorubicin in induction therapy is reported effective and result in a more rapid response
      and a higher response rate than does the conventional dose, without additional toxic effects
      in elderly AML patients between 60 to 65 years.Higher Overall survival rate and Event-free
      survival rate was obtained in escalated group compared with conventional dose. We are
      wondering if Chinese older AML patients can benefit from this escalated induction regimen.

      High dose cytarabine in AML consolidation is reported improving the survival of elderly AML
      patients than the conventional dose，but it is not determined in Chinese older adult AML
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete remission rate in different risk group</measure>
    <time_frame>2 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>escalated daunorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daumorubicin 60mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard daunorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daunorubicin 45mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medium dosage cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g/m2 q12h for 3 days as consolidation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dosage cytarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg/m2 cytarabine for 6 days combined with aclacinomycin 20mg per day for 6 days as consolidation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses</description>
    <arm_group_label>escalated daunorubicin</arm_group_label>
    <arm_group_label>standard daunorubicin</arm_group_label>
    <other_name>daunomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.</description>
    <arm_group_label>escalated daunorubicin</arm_group_label>
    <arm_group_label>standard daunorubicin</arm_group_label>
    <arm_group_label>medium dosage cytarabine</arm_group_label>
    <arm_group_label>standard dosage cytarabine</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary AML（except APL patients）;

          -  ECOG PS:0-2

        Exclusion Criteria:

          -  AML patient who has already received induction treatment, no matter what the outcome
             is;

          -  Treatment-related AML;

          -  Active cancer patients who's condition need to be treated;

          -  The one with serious infectious diseases（eg.uncontrolled tuberculosis or invasive
             pulmonary aspergillosis）

          -  Active heart disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianxiang Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunlin - Zhou, MD</last_name>
    <phone>+8613820429085</phone>
    <email>zcl7317@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Treatment and Diagnosis Center of Leukemia</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianxiang Wang, MD</last_name>
      <phone>+862223909120</phone>
      <email>wangjx@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chunlin Zhou, MD</last_name>
      <phone>+8613820429085</phone>
      <email>zcl7317@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>May 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jianxiang Wang</investigator_full_name>
    <investigator_title>vise-president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

